IGeneX Inc.

556 Gibraltar Drive
Milpitas, CA 95035
T: (800) 832-3200
F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
CALIFORNIA: CLF 4033
NPI: 1396837605

REFERRING PHYSICIAN

TEST DOCTOR

TEST PATIENT
DOB:
Gender:
Accession:
Patient ID:

Collected:
Received:
Reported:
Reprinted:
Amended:
Corrected:

BORRELIOSIS - Lyme Disease

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Lyme ImmunoBlot IgM	Serum			
IGX Criteria:		Negative		
CDC/NYS Criteria:		Negative		

Lyme ImmunoBlot IgM detects antibodies to B. burgdorferi strains and species

Band (kDa)	23*	31*	34*	39*	41*	93
Intensity	IND	-	-	-	IND	-

Band Intensity: Positive: + to ++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION	IGX CRITERIA	CDC/NYS CRITERIA
Positive	2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41* kDa	2 or more of the following bands are present (+): 23*, 39*, 41* kDa
Negative	Does not meet IGX criteria for a positive.	Does not meet CDC/NYS criteria for a positive.

LIMITATION: Bands 31* and 34* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

End of Report

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.